Fig. 2From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysisPatients categorized under WHO functional classification after treatment with ambrisentan (ITT population-LOCF): post-hoc analysis of CTD-PAH and IPAH/HPAH sub-groups. CTD, connective tissue disease; HPAH, Heritable PAH; IPAH, Idiopathic PAH; ITT, intent-to-treat; LOCF, last observation carried forward; PAH, pulmonary arterial hypertension; WHO, World Health OrganisationBack to article page